Sleep Tech Demand Fuels ResMed

Why It Matters

The results prove ResMed’s successful transition to a high‑margin, recurring‑revenue health platform, offering investors durable growth despite potential pharmaceutical disruption.

Key Takeaways

• Revenue up 11% YoY, reaching $1.4 billion
• Gross margin rose to 61.8%, +320 bps
• Software SaaS drives recurring, high‑margin revenue
• CPAP market faces potential 15% shrink from weight‑loss drugs
• Operating cash flow $340 million, strong liquidity

Pulse Analysis

ResMed has quietly reinvented itself from a pure‑device maker into a cloud‑enabled health platform. By coupling CPAP machines and masks with a subscription‑based software suite, the company captures both the initial hardware sale and the ongoing consumable and data‑service revenue streams. The broader sleep‑apnea market remains heavily underdiagnosed, and aging populations combined with rising obesity rates are expanding the addressable pool. Wearable‑driven health awareness further fuels demand for professional diagnosis, giving ResMed a growing base of patients to enroll in its digital ecosystem.

The latest Q2 FY2026 results underscore the payoff of that strategy. Revenue climbed 11% year‑over‑year to $1.4 billion, while gross margin surged to 61.8%, a 320‑basis‑point improvement driven by a higher‑margin product mix and lower component costs. Operating income rose 18%, reflecting operating leverage as fixed costs lagged revenue growth. Software subscriptions and mask accessories now contribute a sizable share of earnings, turning the business into a quasi‑software model. With $340 million of operating cash flow and $1.42 billion of cash on hand, liquidity remains robust.

Looking ahead, ResMed faces a credible long‑term headwind from GLP‑1 weight‑loss drugs that could shrink the CPAP market by up to 15% if they achieve broad adoption. Nonetheless, adherence challenges and the clinical superiority of device‑based therapy suggest a near‑term cushion. Competitive pressure may also return as rivals recover from past recalls, and shifting reimbursement policies could affect pricing. Investors are therefore weighing the company’s high‑margin, recurring‑revenue engine against these uncertainties, but the current earnings trajectory positions ResMed as a durable player in the expanding digital‑health landscape.